The role of model informed drug development practices as applied to COVID will be discussed. It will include commentary on the application of viral cell cycle models, epidemiological models, health economic models to guide treatment considerations. It will also include consideration of PKPD assumptions, the application of physiological based PK modelling, model based metanalyses and how insights derived from model based methods can inform clinical trial design, individual and combination treatment and regimen selection for COVID-19, timing of intervention within the disease course, likely impact on individual versus population health goals.
Upon completion the participant will be able to recognise that COVID-19 is complex disease and that intervention strategies need to be aligned with the disease pathophysiology
Upon completion the participant should be able to recognise that therapeutic interventions can be positioned to address multiple audiences and address both individual and population health treatment perspectives..
Upon completion the participant should be able to recognise the potential for MIDD to improve the effectiveness of the therapeutics response to COVID-19
Upon completion participants will be able to recognise where model informed drug development methods have application in the development of intervention strategies for COVID-19